Frentizole
Based on 1 Customer Validation
Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.48%
- No. CAS: 26130-02-9
- Fòrmula: C15H13N3O2S
- Peso molecular:299.35
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | IC50 |
31 μM
Compound: Frentizole
|
Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 27287370] |
| CHO-K1 | IC50 |
46 μM
Compound: Frentizole
|
Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by LDH assay
Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by LDH assay
|
[PMID: 27287370] |
Frentizole (500 ng/mL, 48 hours) is effective in inhibiting thymidine incorporation into DNA when adds to lymphocyte cultures alongside mitogens, and significantly inhibits the response to concanavalin A by 58% in a dose-dependent manner in lymphocytes extracted from mice peritoneal cavity[1].
Frentizole (62.5 ng/mL) can effectively inhibit uridine incorporation and the inhibition of uridine incorporation is independent of the phytochemical used[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NZB/NZW mice[2]
-
Dosage:8.2 or 79.9 mg/kg/day for young mice
-
Administration:In animal feedings; 52 weeks
-
Result:Showed that the average lifespan of young untreated mice was 38 weeks, in the low dose group the average lifespan was about 38 weeks, and in the high dose group the lifespan was significantly longer with an average lifespan of about 61 weeks.
Significantly suppressed leukocyte counts, compared to a mean peripheral blood leukocyte count of 4160 in control mice, 3217 in low dose treated mice and 3450 in high dose treated mice.
Significant increased in terminal neutrophil counts in young low and high dose treated mice compared to control.
Chemical Information
-
No. CAS 26130-02-9
-
Appearance Solid
-
Peso molecular 299.35
-
Fòrmula C15H13N3O2S
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC=C1)NC2=NC3=CC=C(OC)C=C3S2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvente y solubilidad
DMSO : 12.5 mg/mL (41.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (4.18 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.25 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Meisel AD, et al. Effect of frentizole on mitogen-induced blastogenesis in human lymphocytes. J Immunopharmacol. 1979;1(4):483-95. [Content Brief]
[2]. Walker SE, et al. Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole. Arthritis Rheum. 1982 Nov;25(11):1291-7. [Content Brief]
[3]. Yuli Xie, et al. Identification of small-molecule inhibitors of the Abeta-ABAD interaction. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4657-60. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3406 mL | 16.7029 mL | 33.4057 mL | 83.5143 mL |
| 5 mM | 0.6681 mL | 3.3406 mL | 6.6811 mL | 16.7029 mL | |
| 10 mM | 0.3341 mL | 1.6703 mL | 3.3406 mL | 8.3514 mL | |
| 15 mM | 0.2227 mL | 1.1135 mL | 2.2270 mL | 5.5676 mL | |
| 20 mM | 0.1670 mL | 0.8351 mL | 1.6703 mL | 4.1757 mL | |
| 25 mM | 0.1336 mL | 0.6681 mL | 1.3362 mL | 3.3406 mL | |
| 30 mM | 0.1114 mL | 0.5568 mL | 1.1135 mL | 2.7838 mL | |
| 40 mM | 0.0835 mL | 0.4176 mL | 0.8351 mL | 2.0879 mL |